CDSCO Issues Advisory to Prevent Misleading Promotion of Prescription Drugs for Obesity

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

CDSCO issues advisory to prevent misleading promotion of prescription drugs for obesity

CDSCO issues advisory against misleading promotion of obesity drugs, emphasizing compliance with regulations and importance of lifestyle changes.

Drug regulator issues advisory to pharmaceutical firms against promoting weight loss drugs - The Tribune

Says drug to be prescribed by medical practioners.

CDSCO Issues Advisory to Curb Misleading Promotion of Prescription Medications for Obesity

Get latest articles and stories on India at LatestLY. The Central Drugs Standard Control Organization (CDSCO) has issued an advisory to pharmaceutical manufacturers, importers, and marketing authorization holders to ensure strict compliance with the provisions of the Drugs and Cosmetics Act, 1940 and Rules, 1945 in the promotion and marketing of prescription medicines, particularly GLP-1 receptor agonists and similar drugs indicated for obesity …

India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory

India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.

Centre warns pharma firms against advertising GLP-1 weight-loss drugs

India’s drug regulator has cautioned pharmaceutical companies against advertising GLP-1 weight-loss drugs to the public, warning that both direct and surrogate promotions could invite regulatory action. The advisory, issued by the Central Drugs Standard Control Organisation (CDSCO), reiterates that prescription medicines cannot be promoted directly to consumers under the Drugs and Cosmetics Act, 1940 and related rules. Authorities said companies…